Please ensure Javascript is enabled for purposes of website accessibility

Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

By Brian Orelli, PhD - Jun 12, 2020 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cheaper insulin is on its way.

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL) and Biocon's Semglee, which is essentially identical to Sanofi's (SNY 1.08%) insulin product Lantus.

The companies didn't disclose what they plan to charge for Semglee when announcing the approval, but Mylan CEO Heather Bresch implied that it would be cheaper than Lantus. "This approval is an important milestone, first and foremost for the millions of patients living with diabetes in the U.S. as we seek to expand their access to insulin through more affordable treatment options."

The opportunity for Mylan and Biocon (which bills itself as India's largest biopharmaceutical) is substantial; IQVIA estimates that Sanofi took in $1.68 billion in revenue from Lantus vials and $4.33 billion from the Lantus SoloSTAR Pen in the 12-month period that ended in April.

Hands using a glucose monitor

Image source: Getty Images.

Rather than having Semglee approved as a generic drug or a biosimilar, the companies used the 505(b)(2) pathway, which allows drugmakers to get equivalent drugs approved using the safety data from the original approval. That path is often used when the route of administration is being changed -- from oral to injection, for instance -- but both Semglee and Lantus are injected and available in a vial or in a pre-filled pen.

The companies ran two clinical trials, Instride 1 and Instride 2, which demonstrated there was no difference in safety, efficacy, and immunogenicity between Semglee and Lantus in patients with type 1 and type 2 diabetes. Mylan will sell the drug in the U.S., as well as Canada, Australia, New Zealand, the EU, and European Free Trade Association countries, while Biocon has exclusive rights for Japan and a few emerging markets. Elsewhere, the companies will share commercialization rights for the drug, which has been approved in more than 45 countries.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viatris Inc. Stock Quote
Viatris Inc.
Sanofi Stock Quote
$49.71 (1.08%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.